Skip to content Skip to left sidebar Skip to footer

Bulletin

COVID-19 Vaccine Ordering Deadline

COVID-19 Vaccine Ordering Deadline 

The Philadelphia Department of Public Health (PDPH) Immunization Program would like to remind COVID-19 providers that the deadline to order COVID-19 vaccine is Wednesday at 5pm for orders placed both through Philavax and Monday.com. Orders placed after the deadline will not be processed.

Vaccine orders are delivered on the following Tuesday or Wednesday; please plan accordingly for upcoming clinics.

Quick Steps to Order:

Going forward, the Immunization Program will not process any orders that do not have a closed reconciliation and submitted temperatures by Wednesday at 5PM.

If you have questions, please reach out to vaccines@phila.gov.

Did Your Patient Receive a COVID-19 Vaccination Outside the United States?

Did Your Patient Receive a COVID-19 Vaccination Outside the United States?

Have questions? The “People vaccinated outside the United States” section of the CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines provides guidance on different scenarios.

Talk to your patient and gather the initial information:

  1. Which COVID-19 vaccine did the patient receive?
  2. Is the COVID-19 vaccine authorized by the United States Food and Drug Administration (FDA) or listed for emergency use by the World Health Organization (WHO)?
  3. Did your patient complete a full series of this COVID-19 vaccine (e.g. receive both doses if two doses are recommended)?

Guidelines as of 7/15/21:

US FDA-authorized COVID-19 vaccines:

  • Pfizer-BioNTech (Comirnaty, Tozinameran; mRNA nucleoside modified) – 2 doses
  • Moderna (Spikevax; mRNA nucleoside modified) – 2 doses
  • Johnson & Johnson / Janssen (Ad26.COV2-S recombinant) – 1 dose

COVID-19 vaccines listed for emergency use by the WHO:

  • US FDA-authorized vaccines above
  • AstraZeneca-Oxford (Covishield, Vaxzevria; ChAdOx1-S recombinant) – 2 doses
  • Sinopharm (Vero Cell inactivated) – 2 doses
  • Sinovac (Vero Cell inactivated) – 2 doses

See the table below for a summary of recommendations for patients who received a COVID-19 vaccination outside of the US:

Resources:

Thank you for keeping Philadelphia safe and healthy! If you have any questions, please email vaccines@phila.gov.

Providers Must Fill Out COVID-19 Vaccine Provider Attestation Form by July 13th

Providers Must Fill Out COVID-19 Vaccine Provider Attestation Form by July 13th

PDPH is requesting that all current COVID-19 Vaccine Providers complete the following attestation form. It will collect information on reporting, AEs, and general COVID-19 storage/handling.

This form needs to be completed prior to Tuesday 7/13/21 at COB. 

Click here to fill out the COVID-19 Vaccine Provider Attestation Form!

If you have any questions, please contact vaccines@phila.gov.

Thank you in advance for your time.

Enroll as a COVID-19 Vaccine Provider!

Enroll as a COVID-19 Vaccine Provider!

Not offering COVID-19 Vaccine at your practice yet? If your site has not already enrolled as a COVID-19 Vaccine Provider, you can enroll now to make sure your adolescent patients can get vaccinated this summer!

Click Here to Enroll in Our COVID-19 Vaccine Program!

Becoming a COVID-19 Vaccine Provider

Here are some important things to know about becoming a COVID-19 vaccine providers:

  • You don’t need to purchase new storage units to store the COVID vaccine. No ultralow cold freezer needed.
  • Pfizer can now be stored at refrigerated temperatures for 1 month (31 days) and you can order as few as 54 doses at a time.
  • You are not required to offer vaccine to the general public or offer walk-in vaccination to become a COVID provider.
  • COVID-19 vaccines can be co-administered with other vaccines during the same visit. Click here to read more about Interim Clinical Considerations for Vaccine Coadministration.
  • PDPH is asking providers to ensure vaccination of all eligible patients, even if it means leaving some doses unused or wasted. Wastage does not negatively impact a provider but is simply a means for accounting for inventory. Click here to read more about Vaccine Wastage Guidance.

For more details, please visit our webpage.

Have additional questions or concerns about becoming a COVID-19 vaccine provider? Email your questions to vaccines@phila.gov.

General, Pregnancy, and Pediatric COVID-19 Vaccine FAQ Sheets

General, Pregnancy, and Pediatric COVID-19 Vaccine FAQ Sheets

The Philadelphia Immunization Program has received many questions from residents about the Pfizer, Moderna, and Janssen (J&J) COVID-19 Vaccines. It the vaccine safe? Is it effective? What are the side effects?

To help answer these questions, we have created a General COVID-19 Vaccine FAQ sheet, as well as specific Pregnancy and Pediatric FAQ sheets in seven different languages. The FAQ sheet compiles the ten most frequently asked questions about the Pfizer and Moderna COVID-19 vaccine by Philadelphia residents. Please select and download one of the files below and share it among your network.

General COVID-19 FAQ Sheets:

Pregnancy COVID-19 FAQ Sheets:

Pediatric COVID-19 FAQ sheets:

Don’t see your question listed? Please visit the city’s COVID-19 webpage for more FAQs and updates about the vaccine. Thank you for all you do to help keep Philadelphia safe and healthy!

COVID-19 Vaccine Provider Capacity Survey

COVID-19 Vaccine Provider Capacity Survey

Dear COVID-19 Vaccine Providers,

The Philadelphia Department of Public Health (PDPH) is currently matching COVID-19 vaccine providers with Philadelphia organizations who are seeking vaccinations for members of their community.

If your site is interested in partnering with a local community organization, house of worship or other group to hold a clinic, please fill out the Vaccine Provider Capacity Survey by clicking on the link below.

This brief survey will provide PDPH with an idea of your site’s requirements when matching you with an organization seeking vaccinations.

Click here to Take Our Vaccine Provider Capacity Survey!

Even if your site is currently partnering with organizations to hold clinics, we still ask that you fill out a survey to provide information regarding your site’s needs going forward. If you have questions, please don’t hesitate to reach out to vaccines@phila.gov.

Thank you for helping keep Philly healthy!

COVID-19 Vaccine Pop-up Clinic Calendar

COVID-19 Vaccine Pop-up Clinic Calendar

COVID-19 Providers,

The Philadelphia Department of Public Health (PDPH) wants to hear about your upcoming COVID-19 Vaccination Pop-up and Clinic events! Providers can use the form below to submit information regarding upcoming COVID-19 vaccination events.

Submitted pop-up clinics and events will get added to a calendar which will be posted on the city website to improve vaccination access and awareness within the city.

Please complete the form in its entirety if you would like to feature any of your upcoming events.

Click here to submit your site’s pop-up clinic to our Calendar!

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.

Check Your COVID-19 Vaccine Expiration Dates

Check Your COVID-19 Vaccine Expiration Dates

Several lots of Pfizer, Moderna, and J&J COVID-19 vaccine product have their expiration dates in June and July. Please be mindful of when your COVID-19 vaccine expires!

Remember, always check the product’s expiration dates prior to administering. For Pfizer and Moderna, immediately remove and properly dispose of expired doses as medical waste in order to avoid administration of expired doses. Expired Janssen/J&J doses can be quarantined at this time pending stability studies (DO NOT USE these expired loses in the interim).

Waste is required to be reported to The Philadelphia Department of Public Health (PDPH) via the following form: COVID-19 Vaccine Wastage Adjustments

Pfizer

Expiration Dates are on the vials and can also be found in PhilaVax with the shipment information.

Please note: Pfizer has been approved for storage at standard refrigerator temperatures for 1 month (i.e., 31 days). Prior to being placed in the refrigerator, Pfizer can also be kept at standard freezer temperatures for 2 weeks.

Moderna

Vial Expiration Date Lookup | Moderna COVID-19 Vaccine (EUA)

Please note: Vials can be used for up to 12 hours after being punctured.

J&J

Janssen COVID-19 Vaccine Product Quality Checker

Please note: The FDA has authorized an extension of the Jassen/J&J vaccine’s shelf life from 3 months to 4.5 months.

Quick Reference Guide

Please refer to the COVID-19 Vaccine Quick Reference Guide for Healthcare Professionals to see a storage/handling, administration, and general comparison of the three COVID-19 vaccines. This guide is extremely useful and can be printed for posting at provider locations.

MenQuadfi (MenACYW-TT), a New Meningococcal Vaccine, is Now Available for VFC

MenQuadfi (MenACYW-TT), a New Meningococcal Vaccine, is Now Available for VFC

To download a PDF version of this PDF, click here!

In 2020, the Food and Drug Administration licensed an additional meningococcal serogroups A, C, W, and Y (MenACWY) – MenQuadfi
(MenACYW-TT), from Sanofi Pasteur Inc.

MenQuadfi is now available for providers enrolled in the Vaccines for Children (VFC) program. This advisory includes an overview
of important information about MenQuadfi.

MenQuadfi is licensed for use in individuals 2 years and older in the United States.

Recommendations For Use

Eligible Groups for Receipt of VFC Supplies of MenQuadfi

VFC supplies of MenQuadfi may be given to VFC-eligible children aged 2 years through 18 years.

Licensed Dosing Schedule

MenQuadfi is for intramuscular use only.

MenQuadfi is approved for routine vaccination of children and teens, age 11 through 18 years: a single dose at age 11 or 12 years with a booster dose at age 16 years.

MenQuadfi may also be used for children at increased risk who are age 2 years and older (the primary dosing schedule and booster dose interval varies by age and indication):

  • People with functional or anatomic asplenia
  • People who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor (eculizumab [Soliris] or ravulizumab [Ultomiris])
  • People who have HIV infection
  • People who are at risk during an outbreak caused by a vaccine serogroup
  • People age 2 months and older who reside in or travel to certain countries in sub-Saharan Africa as well as to other countries for which meningococcal vaccine is recommended (e.g., travel to Mecca, Saudi Arabia, for the annual Hajj)
  • Microbiologists who work with meningococcus bacterial isolates in a laboratory
  • First-year college students living in residence halls who are unvaccinated or undervaccinated; these students should receive a dose if they have not had a dose since turning 16 or if it has been more than 5 years since their previous dose

These recommendations are summarized in Table 3 of the recommendations published by ACIP in MMWR in 2020: www.cdc.gov/mmwr/volumes/69/rr/pdfs/rr6909a1-H.pdf.

The Advisory Committee on Immunization Practices (ACIP) recommends that whenever feasible, the same manufacturer’s brand should be used to complete the series. However, if the previous brand is unavailable or unknown, any brand may be used to complete the series. Do not defer immunization solely to wait for a specific meningococcal vaccine brand to be available. From age 2 years and up the MenACWY vaccines are interchangeable.

Storage

  • MenQuadfi should be stored at 2º to 8ºC (36º to 46ºF). Do not freeze. Product which has been exposed to freezing should not be used. Do not use after the expiration date shown on the label.

How MenQuadfi is supplied

  • MenQuadfi is supplied in a single-dose vial in packages of 5 vials (NDC No. 49281-0590-05). The dosage for MenQuadfi is 0.5 mL. MenQuadfi does not contain a preservative. The vial stopper for this product is not made with natural latex rubber.

Ordering and Billing

MenQuadfi is available for ordering through the PhilaVax IIS as of today, June 8, 2021. Please contact Christine Wilson (Christine.Wilson@phila.gov) or Charma Miller (Charma.Miller@phila.gov) to add MenQuadfi to your next order. Please note, your practice must choose a single product to order for each antigen. We recommend that sites that are part of a system, or are affiliated, use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

  • CVX code: 203
  • CPT code: 90619

Resources

Vaxelis (DTaP-IPV-Hib-HepB), a Hexavalent Vaccine, is Now Available for VFC

Vaxelis (DTaP-IPV-Hib-HepB), a Hexavalent Vaccine, is Now Available for VFC

To download a PDF version of this notice, click here!

Vaxelis is now available for providers enrolled in the Vaccines for Children (VFC) program. This advisory includes an overview of important information about Vaxelis.

Vaxelis is a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP) adsorbed, inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib, PRP-OMP), and hepatitis B (HepB) (recombinant) vaccine. In 2018, FDA licensed Vaxelis for use in children age 6 weeks through 4 years: it is indicated as a 3-dose series for infants at ages 2, 4, and 6 months. ACIP voted to add Vaxelis to the Vaccines for Children (VFC) Program in 2019. Vaxelis became commercially available in the United States in 2021.

Recommendations For Use

Eligible Groups for Receipt of VFC Supplies of Vaxelis

VFC supplies of Vaxelis may be given to VFC-eligible children from 6 weeks through 4 years of age (prior to the 5th birthday).

Licensed Dosing Schedule

Vaxelis is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. Vaxelis is approved for use as a 3-dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday). Vaxelis is indicated for use in infants at ages 2, 4, and 6 months.

Recommended minimum ages for administration of Vaxelis (DTaP-IPV-Hib-HepB) vaccine and intervals between doses — United States, 2020*

Age/Interval
Minimum age for any dose 6 weeks
Minimum interval between doses 1 and 2 4 weeks
Minimum age for dose 2 10 weeks
Minimum interval between doses 2 and 3 4 weeks
Minimum age for dose 3 24 weeks†
Maximum age for any dose 4 years, 364 days (do not administer on or after the fifth birthday)

† If the third dose of DTaP-IPV-Hib-HepB is given before age 24 weeks, an additional dose of hepatitis B vaccine should be given at
age ≥24 weeks to complete the hepatitis B series.

*DTaP-IPV-Hib-HepB can be used for children aged <5 years requiring a catch-up schedule. However, vaccine doses should not be
administered at intervals less than the minimum intervals indicated in this table.

For guidance on transitioning to Vaxelis and how it fits into the immunization schedule, visit: https://www.vaxelistransition.com.

The Advisory Committee on Immunization Practices (ACIP) recommends that whenever feasible, the same manufacturer’s brand should be used to complete the series. However, if the previous brand is unavailable or unknown, any brand may be used to complete the series. Do not defer immunization solely to wait for a specific brand to be available.

Storage

Vaxelis should be stored at 2º to 8ºC (36º to 46ºF). Do not freeze. Product which has been exposed to freezing should not be used. Do not use after the expiration date shown on the label.

How Vaxelis is supplied

Vaxelis is supplied in a single-dose vial in packages of 10 vials (NDC no. 49281-0590-05). The dosage for Vaxelis is 0.5 mL. Vaxelis does not contain a preservative. The vial stopper, syringe plunger stopper, and syringe tip cap are not made with natural rubber latex.

Administration

Just before use, shake the vial or syringe until a uniform, white, cloudy suspension results.

Inspect the vial or syringe for particulate matter and discoloration prior to administration. If either of these conditions exist, the product should not be administered.

Administer a single 0.5 mL dose of Vaxelis intramuscularly. In infants younger than 1 year, the anterolateral aspect of the thigh is the preferred site of injection. The vaccine should not be injected into the gluteal area.

Vaxelis should not be combined through reconstitution or mixed with any other vaccine. Discard unused portion. Vaxelis is for intramuscular use only.

Precautions and Contraindications

Do not administer Vaxelis to anyone with a history of severe allergic reaction to a previous dose of Vaxelis, any ingredient of Vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.

Do not administer Vaxelis to anyone with a history of encephalopathy within 7 days of a pertussis containing vaccine with no other identifiable cause.

Do not administer Vaxelis to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.

Ordering and Billing

Vaxelis is available for ordering through the PhilaVax IIS as of today, June 8, 2021. Please contact Jillian Brown (Jillian.Brown@phila.gov) to begin the process of transitioning to Vaxelis at your site. Please note, your practice must choose a single type of combination vaccine to use as part of the primary series. We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

  • CVX code: 146
  • CPT code: 90697

Resources

Vaccine Information Statements (VIS):

CDC Morbidity and Mortality Weekly Report (MMWR): https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6905a5-H.pdf.

For guidance on transitioning to Vaxelis and how it fits into the immunization schedule, visit: https://www.vaxelistransition.com.

Product insert for Vaxelis includes additional vaccine information, found at: https://www.merck.com/product/usa/pi_circulars/v/vaxelis/vaxelis_pi.pdf.

Additional information on vaccines and vaccine preventable diseases can be found at: http://www.cdc.gov/vaccines/